Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Charcot-Marie-Tooth disease
Biotech
Pharnext blames ‘unexpected’ placebo results for phase 3 failure
Less than a year after Pharnext dropped its Alzheimer’s work, the biotech has seen its lead program fail a trial in a rare neurological disease.
James Waldron
Dec 11, 2023 9:18am
Acceleron ditches midstage drug after flop
Mar 10, 2020 7:20am
Neurogene nets $68.5M to advance therapies for neuro diseases
Feb 12, 2019 7:47am
